ARTICLE | Clinical News

Revimid orally available structural analog of thalidomide regulatory update

September 4, 2001 7:00 AM UTC

CELG received U.S. Patent No. 6,281,230 covering compositions of Revimid and use of the product to treat cancer and inflammatory diseases as a single agent and in combination with other therapies. Rev...